Analyst Tycho Peterson discusses Quest Diagnostics (DGX)’ Minimal Residual Disease (MRD) on an Analyst/Industry conference call to be held on October 30 at 2:30 pm. Webcast Link
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics’ AD-Detect Alzheimer’s tests show accuracy in study
- Quest Diagnostics price target raised to $200 from $190 at Piper Sandler
- Quest Diagnostics price target raised to $205 from $195 at Truist
- Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley
- Quest Diagnostics price target raised to $195 from $190 at Barclays